Warren Buffett's Berkshire Hathaway scored a $60 million gain on Biogen shares after they surged to a record high on Monday. Federal regulators approved the biotech company's Aduhelm drug — the ...

Biogen reported second-quarter earnings and revenue that topped estimates and hiked its full-year guidance as cost-cutting efforts showed progress and sales of its breakthrough Alzheimer's drug ...

Biogen expects to do better this year on a key metric of financial health after a strong performance this summer from its newer products, including Leqembi, the closely watched drug for Alzheimer ...

Viehbacher also led Biogen’s largest-ever acquisition last year, buying Reata Pharmaceuticals Inc. for $7.3 billion to gain its approved therapy for Friedreich’s ataxia, a rare ...

Click here for access. * Maintaining their stance, an analyst from Barclays continues to hold a Equal-Weight rating for Biogen, targeting a price of $180. * An analyst from Morgan Stanley has ...

Biogen is the latest big biotech to make a play in protein degradation. The Massachusetts-based company has announced a deal to use Neomorph’s molecular glue degrader discovery platform to go ...

The company's CEO warned on Wednesday that U.S. revenue for Leqembi, which it developed in partnership with Eisai Inc., “continues to be below the expectations of our collaboration.” ...

Morgan Stanley analyst Terence Flynn downgraded Biogen (BIIB) to Equal Weight from Overweight with a price target of $204, down from $285. The firm says the Leqembi launch has tracked below its ...

(RTTNews) - Biogen Inc. (BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer's, rare neurological ...

CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced upcoming data presentations and programming at the Clinical Trials on Alzheimer’s Disease (CTAD ...